Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of ON 123300 for the treatment of cancer

Trial Profile

A phase 1 study of ON 123300 for the treatment of cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs ON 123300 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors HanX Biopharmaceuticals
  • Most Recent Events

    • 13 Nov 2018 According to an Onconova Therapeutics media release, Investigational New Drug (IND) filing is expected to be submitted in the first half of 2019.
    • 24 Apr 2018 New trial record
    • 19 Apr 2018 According to an Onconova Therapeutics media release, HanX Biopharmaceutical plans to initiate a clinical studies in China.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top